# Recent BPC-157 Research: 2024-2026 Studies and Reviews > Recent BPC-157 research from 2024-2026: the first-in-human IV safety pilot, the 2025 musculoskeletal narrative review, the literature-and-patent review, and the newest organ-protection and pain studies — each cited. The freshest readings on the record: two small 2025 human pilots and a dense cluster of 2024-2026 reviews — plotted by year, with each genuine result and each honest gap marked. ## Why recent BPC-157 research reads the way it does Anyone reading recent BPC-157 research — the 2024 through 2026 literature — finds it dominated by review articles and consolidation, punctuated by two small 2025 human pilot reports. The pattern is itself the headline: the field is maturing as a literature faster than it is accumulating new human evidence. Reviewers across this window agree on a single bottom line, which is that the evidence remains overwhelmingly preclinical and that rigorous, large human trials are still lacking [9]. The practical effect for a reader is that the newest sources are excellent for understanding what is claimed and how the mechanisms are proposed to fit together, and weak for answering whether BPC-157 works in people — because the studies that would answer that have not been published. The dated coordinates below separate the two. ## Are there any new BPC-157 studies in 2025? Yes. 2025 was the busiest year in the record, and it was overwhelmingly a review year with two human-adjacent firsts. It brought a first-in-human intravenous safety pilot [8]; a narrative review of BPC-157 for musculoskeletal healing [9]; a literature-and-patent review cataloguing the peptide's multifunctional preclinical activity [11]; a safety-and-intoxication review reasserting the cytoprotectant framing [13]; an acute-pancreatitis rat study reporting reduced distant-organ damage [12]; and a cytoprotectant commentary restating the mechanistic claims [15]. The single most consequential 2025 entry is the safety pilot, because it is the first controlled human exposure on the record — and, at two subjects, also the clearest illustration of how thin the human evidence is [8][14]. ## The two 2025 human pilots The human leg of the record is two readings, and both are small. The intravenous safety pilot gave two healthy adults `10 mg` on day one and `20 mg` on day two by one-hour infusion; it was well tolerated, with no adverse events and no measurable changes in cardiac, hepatic, renal, thyroid, or glucose biomarkers [8]. It is a safety pilot, not an efficacy trial, and its sample size means it can show the absence of obvious acute harm in two people and nothing more. The 2025 musculoskeletal narrative review is the best single summary of where the human evidence actually stands. It concluded that despite broad preclinical support, human data are extremely limited — only three pilot studies exist — that rigorous large-scale trials are lacking, and that BPC-157 should be considered investigational and used with caution given the regulatory controversy and non-regulated availability [14]. That sentence is the honest center of the entire site. ## Recent narrative and systematic reviews The 2024-2026 review cluster maps the territory. The 2024 intestinal-anastomoses review consolidated improved anastomotic-healing findings across rat models [10]. The 2025 literature-and-patent review catalogued the peptide's proposed possible medical applications [11]. A 2025 review emphasized the reported safety profile and beneficial effects following intoxications [13], and a 2025 commentary reasserted the gastric-pentadecapeptide cytoprotectant framing [15]. A 2026 review bridged the tissue-repair and analgesic literatures, synthesizing how regeneration and pain modulation are proposed to connect [17]. Read together, these BPC-157 reviews are consistent on mechanism and consistent on the caveat: the preclinical breadth is real, the human evidence is not yet there, and the literature still leans heavily on a single foundational research group [14]. ## What the recent record still does not contain Reading the 2024-2026 window for what it lacks is as informative as reading it for what it adds. There is still no randomized, controlled human efficacy trial for any indication. There is still no human dose-finding study, no long-term human safety follow-up, and no human drug-interaction work [14]. The two 2025 human entries — the IV safety pilot and the knee-pain case series referenced within the reviews — are the leading edge of the human record, and they remain pilots [8][14]. The newest review also explicitly addresses the popular claims that circulate ahead of the evidence: weight loss, muscle-building, and testosterone effects are not supported by the published literature, and the 2025 musculoskeletal review notes such claims are unsubstantiated [9]. The shortest accurate summary of recent BPC-157 research is that the literature grew, the consensus on caution held, and the central gap — rigorous human evidence — did not close [14]. For the question-by-question reading of the [BPC-157 safety record](/faq) — liver, kidney, heart, interactions — the FAQ collects what the tiny human dataset and the animal work each support. --- A cobalt-blueprint reading of the BPC-157 record — every finding plotted to its study, the human-data gap left as an open cell, and the FDA 503A status struck before anything else; no clinic at the bench and nothing here dispensed or sold.